- Research works
- 19 ▲ 472% vs 2013–17
- Citations
- 201 10.4 per fractional work
- Top-10% rate
- 8.4% record average 16.5%
- Open access
- 29% world 28%
Not ranked overall: Vicore Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 8.0×. Every wedge is a field page.
Which research topics does Vicore Pharma (Sweden) publish most on?
By volume in 2022–2025: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension Research and Treatments, Health Systems, Economic Evaluations, Quality of Life and Respiratory and Cough-Related Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 2 works
- 2 Pulmonary Hypertension Research and Treatments Pulmonary and Respiratory Medicine 2 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 4 Respiratory and Cough-Related Research Pulmonary and Respiratory Medicine 1 works
- 5 Folate and B Vitamins Research Rheumatology 0 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
- 7 Pharmaceutical Economics and Policy Economics and Econometrics 0 works
- 8 Systemic Sclerosis and Related Diseases Pathology and Forensic Medicine 0 works
- 9 Renin-Angiotensin System Studies Cardiology and Cardiovascular Medicine 0 works
- 10 Innovation Policy and R&D Economics and Econometrics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Vicore Pharma (Sweden)'s research output changed?
Output in 2018–2022 was 472% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Mölndal
- Profu (Sweden)
- Dentsply Sirona (Sweden)
- Antaros Medical (Sweden)
- Institute for Quality Indicators (Sweden)
- Setek Elektronik (Sweden)
- Metso (Sweden)
- I-Tech (Sweden)
- Integrum (Sweden)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.